![]() Read the full story by clicking on this headline.. |
The benefits of Sanofi and Regeneron's anti-inflammatory drug Dupixent set in quickly during a trial to treat "smoker's lung" and lasted for the duration of the 1-year study, French drugmaker Sanofi said late on Sunday. The company said it was discussing with major watchdogs... |
0 Comments
Leave a Reply. |
NewsMaxA conservative American news and opinion website founded by Christopher Ruddy in 1998 & operated by Newsmax Media. Archives
June 2023
Categories |